Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP221980.RAhFwzdNWdVnwoP1PY0fRjLMQz35j83R4-oXf1HwnQouA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP221980.RAhFwzdNWdVnwoP1PY0fRjLMQz35j83R4-oXf1HwnQouA130_assertion type Assertion NP221980.RAhFwzdNWdVnwoP1PY0fRjLMQz35j83R4-oXf1HwnQouA130_head.
- NP221980.RAhFwzdNWdVnwoP1PY0fRjLMQz35j83R4-oXf1HwnQouA130_assertion description "[Standard chemotherapy for adrenocortical cancer currently is under evaluation in the context of the recently completed FIRM-ACT evaluating the combination of mitotane with either streptozocin or etoposide, cisplatin, and doxorubicin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP221980.RAhFwzdNWdVnwoP1PY0fRjLMQz35j83R4-oXf1HwnQouA130_provenance.
- NP221980.RAhFwzdNWdVnwoP1PY0fRjLMQz35j83R4-oXf1HwnQouA130_assertion evidence source_evidence_literature NP221980.RAhFwzdNWdVnwoP1PY0fRjLMQz35j83R4-oXf1HwnQouA130_provenance.
- NP221980.RAhFwzdNWdVnwoP1PY0fRjLMQz35j83R4-oXf1HwnQouA130_assertion SIO_000772 22170383 NP221980.RAhFwzdNWdVnwoP1PY0fRjLMQz35j83R4-oXf1HwnQouA130_provenance.
- NP221980.RAhFwzdNWdVnwoP1PY0fRjLMQz35j83R4-oXf1HwnQouA130_assertion wasDerivedFrom befree-20150227 NP221980.RAhFwzdNWdVnwoP1PY0fRjLMQz35j83R4-oXf1HwnQouA130_provenance.
- NP221980.RAhFwzdNWdVnwoP1PY0fRjLMQz35j83R4-oXf1HwnQouA130_assertion wasGeneratedBy ECO_0000203 NP221980.RAhFwzdNWdVnwoP1PY0fRjLMQz35j83R4-oXf1HwnQouA130_provenance.